GeneDx Holdings Corp. entered into a new $100 million term loan agreement on Feb. 27, 2026 with lenders represented by Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C., with Wilmington Trust, National Association as agent. The loan, priced at Term SOFR plus 4.50% with a 1.50% SOFR floor and maturing five years from closing, was used to repay the company’s existing term loan under its October 2023 credit agreement and is expected to support other balance sheet optimization initiatives and general corporate purposes. The facility is guaranteed by certain subsidiaries and secured by a first-lien interest in substantially all assets, and includes a $50 million minimum liquidity covenant.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001818331-26-000021), on March 02, 2026, and is solely responsible for the information contained therein.
Comments